Glycopyrrolate in 99mTc-pertechnetate brain imaging.

Area of Science:

• Nuclear Medicine
• Pharmacology
• Radiopharmacy

Background:

• 99mTc-pertechnetate brain imaging is a diagnostic tool.
• Choroid plexus, oral mucosa, and salivary glands can exhibit pertechnetate uptake.
• Anticholinergic agents may modulate radiotracer uptake.

Purpose of the Study:

• To evaluate the efficacy of glycopyrrolate in suppressing 99mTc-pertechnetate uptake.
• To assess the impact of glycopyrrolate on specific uptake sites relevant to brain imaging.

Main Methods:

• Parenteral administration of glycopyrrolate to patients undergoing 99mTc-pertechnetate brain imaging.
• Quantification of pertechnetate activity in the choroid plexus, oral mucosa, and salivary glands.

Main Results:

• Glycopyrrolate almost completely eliminated pertechnetate activity from the choroid plexus and oral mucosa.
• A moderate reduction in parotid gland pertechnetate uptake was observed.
• The drug demonstrated potential for oral administration.

Conclusions:

• Glycopyrrolate is effective in suppressing unwanted 99mTc-pertechnetate uptake in brain imaging.
• The drug may enhance the diagnostic quality of pertechnetate brain imaging.
• Glycopyrrolate's potential for oral administration warrants further investigation.